Coronavirus Vaccine Program From Pfizer and BioNTech Reports Preliminary Success

BioNTech (NASDAQ: BNTX) and Pfizer (NYSE: PFE) released clinical trial results regarding the partners' experimental coronavirus vaccine program, BNT162, on Monday. Specifically, the partners published results from an early-stage German trial with BNT162b1, the most advanced candidate in a program designed to test four related vaccine candidates. 

This specific candidate delivers messenger RNA (mRNA) that leads to the production of the receptor-binding domain found on SARS-CoV-2, the virus that causes COVID-19. Results from the German study fell in line with positive results the partners posted earlier this month from a similar study run in the U.S. with an important new revelation.

Image source: Getty Images.

Continue reading

Source Fool.com